UPDATE: Stifel Reiterates On Ophthotech Corp Following 3Q14 Report
In a report published Wednesday, Stifel analyst Stephen Willey reiterated a Buy rating on Ophthotech Corp (NASDAQ: OPHT), and raised the price target from $58.00 to $59.00.
In the report, Stifel noted, “P3 enrollment remains on track and the tivozantib licensing agreement creates some additional low-cost optionality. Increased $59 target (previously $58) reflects refinement of Novartis milestone payments. Remain Buy-rated.”
Ophthotech Corp closed on Tuesday at 41.74.
Latest Ratings for OPHT
Date | Firm | Action | From | To |
---|---|---|---|---|
Mar 2018 | JP Morgan | Downgrades | Neutral | Underweight |
Feb 2018 | Chardan Capital | Maintains | Neutral | Neutral |
Dec 2016 | Gabelli & Co. | Downgrades | Buy | Hold |
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Stephen Willey StifelAnalyst Color Price Target Analyst Ratings